ATE503025T1 - Verfahren zur bestimmung der prognose eines adenokarzinoms - Google Patents
Verfahren zur bestimmung der prognose eines adenokarzinomsInfo
- Publication number
- ATE503025T1 ATE503025T1 AT07799622T AT07799622T ATE503025T1 AT E503025 T1 ATE503025 T1 AT E503025T1 AT 07799622 T AT07799622 T AT 07799622T AT 07799622 T AT07799622 T AT 07799622T AT E503025 T1 ATE503025 T1 AT E503025T1
- Authority
- AT
- Austria
- Prior art keywords
- adenocarcinoma
- prognosis
- determining
- organ
- methods
- Prior art date
Links
- 208000009956 adenocarcinoma Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 238000004393 prognosis Methods 0.000 title abstract 3
- 210000000056 organ Anatomy 0.000 abstract 3
- 102100037850 Interferon gamma Human genes 0.000 abstract 2
- 108010074328 Interferon-gamma Proteins 0.000 abstract 2
- 102000003814 Interleukin-10 Human genes 0.000 abstract 2
- 108090000174 Interleukin-10 Proteins 0.000 abstract 2
- 102000013462 Interleukin-12 Human genes 0.000 abstract 2
- 108010065805 Interleukin-12 Proteins 0.000 abstract 2
- 102000003812 Interleukin-15 Human genes 0.000 abstract 2
- 108090000172 Interleukin-15 Proteins 0.000 abstract 2
- 102000000588 Interleukin-2 Human genes 0.000 abstract 2
- 108010002350 Interleukin-2 Proteins 0.000 abstract 2
- 102000004890 Interleukin-8 Human genes 0.000 abstract 2
- 108090001007 Interleukin-8 Proteins 0.000 abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 2
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83093606P | 2006-07-14 | 2006-07-14 | |
| US88510107P | 2007-01-16 | 2007-01-16 | |
| PCT/US2007/073637 WO2008009028A2 (en) | 2006-07-14 | 2007-07-16 | Methods of determining the prognosis of an adenocarcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE503025T1 true ATE503025T1 (de) | 2011-04-15 |
Family
ID=38670673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07799622T ATE503025T1 (de) | 2006-07-14 | 2007-07-16 | Verfahren zur bestimmung der prognose eines adenokarzinoms |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9464324B2 (de) |
| EP (1) | EP2041313B1 (de) |
| AT (1) | ATE503025T1 (de) |
| DE (1) | DE602007013405D1 (de) |
| WO (1) | WO2008009028A2 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110183859A1 (en) * | 2008-09-25 | 2011-07-28 | The United States Of America, As Represented By The Secretary, | Inflammatory genes and microrna-21 as biomarkers for colon cancer prognosis |
| RU2455924C1 (ru) * | 2011-03-30 | 2012-07-20 | Учреждение Российской академии наук Институт физиологии природных адаптаций Уральского отделения Российской академии наук | Способ прогнозирования метастазирования опухолевого процесса у больных раком желудка |
| US10976318B2 (en) | 2014-02-24 | 2021-04-13 | Immunepharma S.R.L. | Method of treating cancer using a caspase-4 inhibitor |
| CN120148652B (zh) * | 2025-03-14 | 2025-09-23 | 河北医科大学第二医院 | 肺腺癌来源脑膜癌病预后预测方法、装置、电子设备及存储介质 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985829A (en) * | 1994-12-19 | 1999-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Screening assays for compounds that cause apoptosis and related compounds |
| US6368598B1 (en) | 1996-09-16 | 2002-04-09 | Jcrt Radiation Oncology Support Services, Inc. | Drug complex for treatment of metastatic prostate cancer |
| US7049063B2 (en) * | 1998-03-18 | 2006-05-23 | Corixa Corporation | Methods for diagnosis of lung cancer |
| US6960570B2 (en) * | 1998-03-18 | 2005-11-01 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6618679B2 (en) * | 2000-01-28 | 2003-09-09 | Althea Technologies, Inc. | Methods for analysis of gene expression |
| US7171311B2 (en) * | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
| PT1410011E (pt) * | 2001-06-18 | 2011-07-25 | Rosetta Inpharmatics Llc | Diagnóstico e prognóstico de pacientes com cancro da mama |
| AU2002343443A1 (en) | 2001-09-28 | 2003-04-14 | Whitehead Institute For Biomedical Research | Classification of lung carcinomas using gene expression analysis |
| WO2003087766A2 (en) | 2002-04-05 | 2003-10-23 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Methods of diagnosing potential for metastasis or developing hepatocellular carcinoma and of identifying therapeutic targets |
| WO2004005891A2 (en) * | 2002-07-10 | 2004-01-15 | The Regents Of The University Of Michigan | Expression profile of lung cancer |
| WO2004041196A2 (en) | 2002-11-04 | 2004-05-21 | The United States Of America, Represented By The Secretary Of Health And Human Services, Nih | Methods and compositions for the diagnosis of neuroendocrine lung cancer |
| US20030153013A1 (en) * | 2002-11-07 | 2003-08-14 | Ruo-Pan Huang | Antibody-based protein array system |
| AU2003295511A1 (en) * | 2002-11-13 | 2004-06-03 | Genentech, Inc. | Methods and compositions for diagnosing dysplasia |
| AU2003900747A0 (en) * | 2003-02-18 | 2003-03-06 | Garvan Institute Of Medical Research | Diagnosis and treatment of pancreatic cancer |
| US20040229225A1 (en) * | 2003-05-16 | 2004-11-18 | Jose Remacle | Determination of a general three-dimensional status of a cell by multiple gene expression analysis on micro-arrays |
| WO2005015236A2 (en) * | 2003-07-18 | 2005-02-17 | Roche Diagnostics Gmbh | A method for predicting the progression of adenocarcinoma |
| WO2006060653A2 (en) | 2004-11-30 | 2006-06-08 | Veridex Llc | Lung cancer prognostics |
| EP1777523A1 (de) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | In-vitro-Verfahren zur Prognose einer Tumorprogression und des Ergebnisses bei einem Patienten sowie Mittel zur Durchführung dieses Verfahrens |
| WO2007140352A2 (en) * | 2006-05-26 | 2007-12-06 | Invitrogen Corporation | Plasma membrane and secreted cancer biomarkers |
-
2007
- 2007-07-16 AT AT07799622T patent/ATE503025T1/de not_active IP Right Cessation
- 2007-07-16 WO PCT/US2007/073637 patent/WO2008009028A2/en not_active Ceased
- 2007-07-16 US US12/373,191 patent/US9464324B2/en active Active
- 2007-07-16 DE DE602007013405T patent/DE602007013405D1/de active Active
- 2007-07-16 EP EP07799622A patent/EP2041313B1/de not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008009028A3 (en) | 2008-04-10 |
| EP2041313A2 (de) | 2009-04-01 |
| US9464324B2 (en) | 2016-10-11 |
| WO2008009028A2 (en) | 2008-01-17 |
| US20090258789A1 (en) | 2009-10-15 |
| EP2041313B1 (de) | 2011-03-23 |
| DE602007013405D1 (de) | 2011-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE446790T1 (de) | Verfahren zur bestimmung der reichweite von strahlung | |
| WO2006113747A3 (en) | Diagnostic markers of breast cancer treatment and progression and methods of use thereof | |
| TW200741010A (en) | Method for predicting the response to a treatment | |
| UA101301C2 (ru) | ВЫДЕЛЕННОЕ АНТИТЕЛО ПРОТИВ IL-23pl 9 И ЕГО ПРИМЕНЕНИЕ | |
| DE60327603D1 (de) | Chirurgische vorrichtung zur haut-therapie und zum testen | |
| ATE506448T1 (de) | Verfahren zur l-aminosäureherstellung mittels fermentation | |
| WO2009040789A3 (en) | T cell subpopulations capable of treating cancer | |
| DE602007013405D1 (de) | Verfahren zur bestimmung der prognose eines adenokarzinoms | |
| WO2010083252A3 (en) | Ratio based biomarkers and methods of use thereof | |
| TW200745556A (en) | Biomarkers for liver fibrotic injury | |
| GB0701676D0 (en) | Methods and Kit for the Prgnosis of Breast Cancer | |
| WO2012154567A3 (en) | Human invasion signature for prognosis of metastatic risk | |
| EP2212700B8 (de) | Verfahren zur beurteilung von kolorektalem krebs anhand einer stuhlprobe durch verwendung einer marker-kombination aus calprotectin und einem hämoglobin/haptoglobin-komplex | |
| ATE523786T1 (de) | In-vitro-verfahren zur prognose des fortschreitens einer krebserkrankung und des ausgangs für einen patienten sowie verfahren zur durchführung des verfahrens | |
| EP1860553A3 (de) | Verfahren und Vorrichtung zur Virtualisierung von Fensterinformationen | |
| ATE458201T1 (de) | Methode zur beurteilung von rheumatoider arthritis durch bestimmung von anti-ccp und interleukin 6 | |
| WO2005040421A3 (en) | Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues | |
| WO2006131599A3 (en) | Method of profiling a cell population | |
| WO2009003706A3 (en) | Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones | |
| DE50313671D1 (de) | Verfahren zur generierung eines gentechnisch veränderten organismus für das wirksubstanzscreening | |
| ATE446384T1 (de) | Verfahren zur amplifikation von nukleinsäuren mittels promotor-templates | |
| EP4300031C0 (de) | Kornflockenmesssystem und -verfahren sowie kornflockensammel-, bewegungs- und messsystem | |
| BRPI0311182A2 (pt) | método para isolar uma célula endotelial e método para realizar provas cruzadas específicas para o doador | |
| Guangli et al. | Expression of vascular endothelial growth factor and cyclooxygenase-2 in laryngeal squamous cell carcinoma and its significance | |
| EP1456645A4 (de) | Verfahren zur bestimmung der prognose von krebspatienten mittels tucan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |